Evidence map›Paper›PMID 26836284›Full record

ArticleBiochemistry2016

Folding of Fibroblast Growth Factor 1 Is Critical for Its Nonclassical Release.

Igor Prudovsky, Doreen Kacer, Julie Davis, Varun Shah, Srinivas Jayanthi, Isabelle Huber, Rajalingam Dakshinamurthy, Owen Ganter, Raffaella Soldi, David Neivandt and 2 more

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Through the back door: Unconventional protein secretion.Cell surface (Amsterdam, Netherlands) · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Igor PrudovskyMaine Medical Center Research Institute , 81 Research Drive, Scarborough, Maine 04074, United States.
Doreen KacerMaine Medical Center Research Institute , 81 Research Drive, Scarborough, Maine 04074, United States.
Julie DavisDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
Varun ShahDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
Srinivas JayanthiDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
Isabelle HuberDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
Rajalingam DakshinamurthyDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
Owen GanterCollege of Pharmacy, University of New England , Pharmacy Building, 716 Stevens Avenue, Portland, Maine 04103, United States.
Raffaella SoldiMaine Medical Center Research Institute , 81 Research Drive, Scarborough, Maine 04074, United States.
David NeivandtGraduate School of Biomedical Science and Engineering, University of Maine , Jenness Hall, Orono, Maine 04469, United States.
Olgun GuvenchGraduate School of Biomedical Science and Engineering, University of Maine , Jenness Hall, Orono, Maine 04469, United States.
Thallapuranam Krishnaswamy Suresh KumarDepartment of Chemistry and Biochemistry, University of Arkansas , Chemistry Building, Fayetteville, Arkansas 72701, United States.
University of Arkansas at Fayetteville · USMaine Medical Center Research Institute · USUniversity of Maine · USNew England College · US

Funding

Structure based drug discoveryP20RR015569 · NCRR · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2000 to 2009
$21.4M
Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
THE PATHOLOGY OF HUMAN ENDOTHELIAL CELL PHENOTYPESR01HL035627 · NHLBI · MELOY LABORATORIES, INC. · PI PRUDOVSKY, IGOR · 1985 to 2010
$2.3M
Biopolymer-based strategies for local delivery of cytokine therapeuticsR01CA172631 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI ZAHAROFF, DAVID · 2014 to 2018
$1.5M
NCI NIH HHS R01 CA172631NCRR NIH HHS 1 P20RR15569NCRR NIH HHS P20 RR015569NHLBI NIH HHS R01 HL035627NIGMS NIH HHS P30 GM103392NIGMS NIH HHS P30GM103392NIGMS NIH HHS P30 GM103450
6 · The paper itself

Abstract

Fibroblast growth factor 1 (FGF1), a ubiquitously expressed pro-angiogenic protein that is involved in tissue repair, carcinogenesis, and maintenance of vasculature stability, is released from the cells via a stress-dependent nonclassical secretory pathway. FGF1 secretion is a result of transmembrane translocation of this protein. It correlates with the ability of FGF1 to permeabilize membranes composed of acidic phospholipids. Like several other nonclassically exported proteins, FGF1 exhibits β-barrel folding. To assess the role of folding of FGF1 in its secretion, we applied targeted mutagenesis in combination with a complex of biophysical methods and molecular dynamics studies, followed by artificial membrane permeabilization and stress-induced release experiments. It has been demonstrated that a mutation of proline 135 located in the C-terminus of FGF1 results in (i) partial unfolding of FGF1, (ii) a decrease in FGF1's ability to permeabilize bilayers composed of phosphatidylserine, and (iii) drastic inhibition of stress-induced FGF1 export. Thus, folding of FGF1 is critical for its nonclassical secretion.

Indexed as

Cell Membrane PermeabilityModels, MolecularProtein FoldingAmino Acid SubstitutionAnimalsCalorimetry, Differential ScanningFibroblast Growth Factor 1HEK293 CellsHumansKineticsLipid BilayersMembranes, ArtificialMiceMolecular Dynamics SimulationMutationNIH 3T3 CellsFibroblast Growth Factor 1Lipid BilayersMembranes, ArtificialPhosphatidylserinesRecombinant Proteins

Identifiers

PMID26836284
PMCPMC5534326
OpenAlexW2256456616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.